White Matter Development and Executive Outcomes Following Pediatric Brain Tumor Treatment

Advances in cancer treatments have significantly improved survival rates for childhood cancers. However, many survivors experience persistent neurocognitive difficulties. Rapid brain development during childhood involves the maturation of cerebral white matter, which is essential for executive functions. Although pediatric cancer treatments are known to impact the developing brain, the influence of developmental timing on long-term outcomes is unclear. It is not well understood how age at exposure to cancer treatments affects white matter and executive function development. The general problem addressed here is whether treatment during early stages of brain maturation leads to greater and more persistent neurocognitive disruption. Younger age at exposure to pediatric cancer treatments is associated with greater alterations in white matter and executive function outcomes. Across numerous studies, early treatment has been linked to disruption of frontal and fronto-parietal white matter pathways, which are critical for cognition. These findings suggest that while developmental neuroplasticity allows for some functional compensation, it does not fully prevent long-term changes to cognitive decline. Together, these results emphasize the importance of developmental timing in pediatric cancer survivors.